Major
Established
説明
Combining rivaroxaban with clopidogrel substantially increases bleeding risk through simultaneous inhibition of factor Xa and platelet P2Y12 receptors.
機序
Rivaroxaban inhibits factor Xa, preventing thrombin generation and fibrin clot formation; clopidogrel irreversibly blocks ADP-mediated platelet activation. The combined antithrombotic burden is greater than either alone.
臨床的意義
Clinical trial data (PIONEER AF-PCI) demonstrate significantly higher bleeding rates with this combination, particularly GI hemorrhage.
対処法
Minimize duration of dual therapy to the lowest risk-stratified period; add gastroprotection; reassess at each visit whether both agents are still needed.